Immunotherapy in Gastrointestinal Cancers

Table 3

Ongoing studies on hepatocellular carcinoma.

Trial (ClinicalTrials.gov identifier)	Setting	Phase	Study interventions	Number of patients	Primary endpoint
Checkpoint inhibitors
NCT02576509 CheckMate459	1st line	III	Nivolumab versus sorafenib in first line	726	OS, ORR
NCT02702414 Keynote 224	2nd line	II	Pembrolizumab in second line	100	ORR
NCT02702401 Keynote 240	2nd line	III	Pembrolizumab versus BSC in second line	408	PFS, OS
NCT01658878 CheckMate 040		I/II	Nivolumab versus nivolumab + Ipilimumab nivolumab	620	AEs, SAEs, ORR
NCT02519348	Advanced	II	Tremelimumab + MEDI4736 versus tremelimumab versus MEDI4736	144	AEs, SAEs, DLTs
Vaccines
NCT01974661	Advanced	I	COMBIG-DC (allogeneic dendritic cells) cancer vaccine	18	Safety and tolerability
Cytokines
NCT02632188	Resected	I/II	SURGERY → DC-PMAT treatment	60	PFS
NCT02873442	Advanced	I/II	TACE versus TACE + precision cell immunotherapy	40	PFS, OS
NCT02487017	Advanced	II	TACE versus TACE + DK-CIK		OS
CAR-T cells
NCT02729493	Advanced	II	EPCAM-targeted CAR-T cells	25	DCR